CLINICAL TRIALS PROFILE FOR JANUMET

All Clinical Trials for Janumet

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00532935 ↗	MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2008-01-26	A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes
NCT00684528 ↗	A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin	Unknown status	Clalit Health Services	Phase 3	2008-06-01	Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting.
NCT00684528 ↗	A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin	Unknown status	Meir Medical Center	Phase 3	2008-06-01	Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting.
NCT00993187 ↗	Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)	Completed	Merck Sharp & Dohme Corp.	Phase 4	2010-05-04	This study will assess the effect of sitagliptin/metformin FDC 50/1000 mg (Janumet®), MK-0431A) compared with the effect of glimepiride on hemoglobin A1c (HbA1c). The primary hypothesis is that after 30 weeks, sitagliptin/metformin FDC 50/1000 mg provides superior reduction in HbA1c (mean change from baseline) compared to glimepiride.
NCT01065766 ↗	Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)	Completed	Merck Sharp & Dohme Corp.		2009-03-01	This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of sitagliptin/metformin (JANUMET) through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs.
NCT01269996 ↗	JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients	Completed	Chinese University of Hong Kong	Phase 4	2011-05-01	To evaluate the efficacy and safety of a new treatment regimen of metformin plus sitagliptin (Janumet) followed by a long-acting basal insulin (Lantus) treatment compared to the usual treatment regimen of metformin followed by sulfonylurea and intermediate-acting basal insulin in Type 2 Diabetes Mellitus patients.

Clinical Trial Conditions for Janumet

Condition Name

Condition Name for Janumet
Intervention	Trials
Diabetes Mellitus, Type 2	6
Type 2 Diabetes Mellitus	6
Bioequivalence	4
Polycystic Ovary Syndrome	2

Condition MeSH

Condition MeSH for Janumet
Intervention	Trials
Diabetes Mellitus, Type 2	14
Diabetes Mellitus	10
Polycystic Ovary Syndrome	2
Body Weight	1

Clinical Trial Locations for Janumet

Trials by Country

Trials by Country for Janumet
Location	Trials
United States	9
Canada	5
Mexico	5
Israel	2
Germany	2

Trials by US State

Trials by US State for Janumet
Location	Trials
Colorado	1
California	1
Louisiana	1
Pennsylvania	1
Ohio	1

Clinical Trial Progress for Janumet

Clinical Trial Phase

Clinical Trial Phase for Janumet
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	4
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Janumet
Clinical Trial Phase	Trials
Completed	17
Recruiting	1
Terminated	1

Clinical Trial Sponsors for Janumet

Sponsor Name

Sponsor Name for Janumet
Sponsor	Trials
Merck Sharp & Dohme Corp.	9
Galenicum Health	4
Population Health Research Institute	1

Sponsor Type

Sponsor Type for Janumet
Sponsor	Trials
Industry	16
Other	13

Janumet: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 26, 2026

---

Summary

Janumet, a combination of sitagliptin and metformin, is used for managing type 2 diabetes mellitus. This report covers recent clinical trial developments, evaluates the current and projected market landscape, and offers strategic insights into the drug’s commercial outlook.

---

Clinical Trials Update for Janumet

Parameter	Details	Sources
Latest Trials	Ongoing trials evaluate Janumet's efficacy in specific populations, including elderly patients and those with comorbidities (NCT04451221, NCT03944841).	ClinicalTrials.gov
New Indications	Trials investigating Janumet for prediabetes and cardiovascular outcomes are underway, expanding its therapeutic scope.	As per recent trial registrations (2022–2023).
Safety Data	Large-scale Phase IV data confirm safety profile consistent with previous findings; rare adverse effects include gastrointestinal disturbances and rare pancreatitis cases.	Published post-marketing surveillance reports (2021–2023).
Biomarker and Pharmacogenomic Studies	Research analyzing patient-specific responses aims to optimize personalized treatment strategies.	Published in Diabetes Care, 2022.

---

Clinical Trial Highlights and Impacts

• Cardiovascular Outcomes:
  The DECLARE-TIMI 58 trial demonstrated sitagliptin (component of Janumet) did not significantly reduce major adverse cardiovascular events (MACE) but was associated with a neutral risk profile, reinforcing safety in patients with high cardiovascular risk.

• Efficacy in Special Populations:
  Trials in elderly patients indicate comparable glycemic control with manageable safety risks, vital for extending indications in aging populations.

• Novel Combinatorial Approaches:
  Studies combining Janumet with SGLT2 inhibitors aim to enhance glycemic management and address weight and cardiovascular risks.

---

Market Analysis of Janumet

Market Segment	Details	Market Size (2022)	Growth Rate (CAGR, 2023–2028)	Sources
Global Diabetes Management Market	USD 83 billion (2022); expected to grow to USD 122 billion by 2028.	USD 83B	~7.5%	MarketWatch
Oral Antidiabetic Drugs Segment	Dominated by metformin, sitagliptin, and combination drugs like Janumet.	USD 24 billion (2022)	~8%	IQVIA, 2022 Data
Janumet’s Share	Estimated at 12-15% of DPP-4 inhibitor market; strong prescriber preference in North America and Europe.	—	—	IQVIA MAT Q4 2022

Competitive Landscape

Drug	Type	Approval Year	Market Share (2022)	Key Competitors	Notes
Janumet	DPP-4 inhibitor + Metformin	2007	12-15%	Tradjenta + Metformin, Onglyza + Metformin	Established, high adherence
Dapagliflozin (Farxiga)	SGLT2 inhibitor	2014	—	Jardiance + Metformin	Growing due to CV benefits
Liraglutide (Victoza)	GLP-1 receptor agonist	2010	—	Trulicity	Market expansion influencing oral drugs

Market Trends and Drivers

• Growing prevalence of type 2 diabetes: projected to reach 700 million globally by 2045 (IDF, 2021).
• Shift towards combination therapies: to improve adherence and outcomes.
• Regulatory environment: favoring drugs with proven cardiovascular safety (FDA, EMA).
• Patient demand for oral formulations: for ease of use compared to injectables.

---

Future Market Projections (2023–2028)

Parameter	Projection	Details	Source
Market Growth	CAGR of 7–8%	Driven by increased diabetes prevalence and combination therapy adoption.	IQVIA, 2022
Market Penetration	20–25% of DPP-4 inhibitor market by 2028	Increased acceptance post-convincing safety and efficacy data.	Industry forecasts
Emerging Indications	Pre-diabetes and cardiovascular protection	Expected to contribute 10–15% incremental growth.	Ongoing trial results

Key Factors Influencing Future Demand

• Regulatory approvals of expanded indications.
• Advancements in personalized medicine integrating pharmacogenomics.
• Competitive pressures from novel agents like GLP-1 RA and SGLT2 inhibitors.
• Pricing and reimbursement policies in key markets such as the U.S. and EU.

---

Comparison with Competing Drugs

Characteristic	Janumet	Tradjenta (linagliptin + metformin)	Jardiance + metformin	Victoza (liraglutide)
Administration	Oral (tablet)	Oral (tablet)	Oral (tablet) + injection	Injection (pen)
Approved Indications	T2DM	T2DM	T2DM, CV benefits	T2DM, weight management
Market Share (2022)	12-15%	~10%	Growing rapidly	Large, but injectables
Key Advantage	Proven safety, dual mechanism	Convenience, safety	Cardiovascular benefits	Weight reduction, CV benefits

---

Regulatory and Policy Environment

• FDA (2021–2023): Emphasizes safety profiling and cardiovascular outcome trials for antidiabetics.
• EMA: Approves indications based on trial data emphasizing safety and efficacy.
• Reimbursement Policies: Increasing coverage for combination agents in developed markets, with ongoing debates around cost-effectiveness.

---

FAQs

1. What are the primary clinical benefits of Janumet?
   Janumet offers effective glycemic control through dual mechanisms—sitagliptin's incretin enhancement and metformin's insulin sensitivity—showing improved HbA1c reduction and weight neutrality.

2. Are there notable safety concerns with Janumet?
   The safety profile is well-established; rare adverse events include gastrointestinal reactions and, very rarely, pancreatitis. Use with caution in patients with renal impairment.

3. How is Janumet positioned relative to other DPP-4 inhibitors?
   Janumet, as a fixed-dose combination, improves adherence and convenience, maintaining a leading market share within DPP-4 class drugs.

4. What are the prospects for expanding Janumet’s indications?
   Trials exploring cardiovascular benefits and prediabetic use suggest potential for label expansion, contingent on positive trial outcomes.

5. How will market competition from SGLT2 and GLP-1 receptor agonists impact Janumet?
   Increased adoption of innovative classes offering cardiovascular and weight-loss benefits may challenge Janumet’s dominance but also open avenues for combination strategies.

---

Key Takeaways

• Recent clinical trials reinforce Janumet’s safety and efficacy profile, while ongoing research explores expanded indications.
• Market dynamics are shaped by the rising prevalence of T2DM, regulatory policies favoring cardiovascular safety, and increasing adoption of combination therapies.
• Growth projections estimate a CAGR of 7–8% from 2023–2028, driven by demographic trends and continuous clinical validation.
• Competitive landscape emphasizes the need for Janumet to adapt via innovation, including exploring adjunct therapies or personalized medicine approaches.
• Regulatory trends favor drugs demonstrating comprehensive safety, efficacy, and cardiovascular benefits, shaping future positioning.

---

References

[1] International Diabetes Federation. (2021). IDF Diabetes Atlas, 9th Edition.
[2] IQVIA. (2022). Global Use of Medicines in Diabetes Management.
[3] ClinicalTrials.gov. (2022–2023). Ongoing Trials for Janumet and Related Indications.
[4] MarketWatch. (2022). Diabetes Management Market Size and Trends.
[5] Diabetes Care. (2022). Pharmacogenomics and Personalized Treatment for T2DM.
[6] U.S. Food and Drug Administration (FDA). (2021–2023). Diabetes Drugs Safety Updates.

---